Floatz Rating
C39/100
Confidence
Indicative
Sponsor
The University of Texas Health Science Center at San Antonio
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06108076CT.gov Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Systolic Heart Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ketone Monoester (this asset) | The University of Texas Health Science Center at San Antonio | Early P1 | C · 39 |
| Pertuzumab | Medstar Health Research Institute | P2 | B |
| Trastuzumab | Medstar Health Research Institute | P2 | B |
| Semaglutide | Jens D Hove, MD,PHD | P2/3 | B |
| Trastuzumab Emtansine | Medstar Health Research Institute | P2 | B |
| Eplerenone | Karolinska Institutet | P2 | CCC |
| Dapagliflozin | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | N/A | D |
| Bortezomib | Oregon Health and Science University | Unk | D |
Other indications for Ketone Monoester
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | Early P1 | C · 36 |
| Obesity Disorder | — | N/A | D · 30 |
| Disorder Of Fatty Acid And Ketone Body Metabolism | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ketone Monoester in Systolic Heart Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ketone-monoester-systolic-heart-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →